Sanofi
SNY
About: Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Employees: 82,878
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
9% more call options, than puts
Call options by funds: $87.6M | Put options by funds: $80.3M
6% more repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 254
6% less funds holding
Funds holding: 756 [Q1] → 709 (-47) [Q2]
11.12% less ownership
Funds ownership: 21.06% [Q1] → 9.94% (-11.12%) [Q2]
18% less capital invested
Capital invested by funds: $14.4B [Q1] → $11.8B (-$2.61B) [Q2]
28% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 97
67% less funds holding in top 10
Funds holding in top 10: 12 [Q1] → 4 (-8) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Morgan Stanley
Mark Purcell
|
$58
|
Overweight
Upgraded
|
8 Sep 2025 |
Financial journalist opinion
Based on 20 articles about SNY published over the past 30 days
